ES2166779T3 - Complejos inmunogenicos del hiv. - Google Patents

Complejos inmunogenicos del hiv.

Info

Publication number
ES2166779T3
ES2166779T3 ES94917313T ES94917313T ES2166779T3 ES 2166779 T3 ES2166779 T3 ES 2166779T3 ES 94917313 T ES94917313 T ES 94917313T ES 94917313 T ES94917313 T ES 94917313T ES 2166779 T3 ES2166779 T3 ES 2166779T3
Authority
ES
Spain
Prior art keywords
hiv
immunogenic complexes
complex
vaccine
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94917313T
Other languages
English (en)
Inventor
Anthony Louis Devico
Ranajit Pal
Mangalasseril G Sarngadharan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux Inc
Original Assignee
Biomerieux Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux Inc filed Critical Biomerieux Inc
Application granted granted Critical
Publication of ES2166779T3 publication Critical patent/ES2166779T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTA UNA VACUNA Y UN METODO PARA ELEVAR LA NEUTRALIZACION DE ANTICUERPOS CONTRA LA INFECCION POR HIV. LA VACUNA COMPRENDE UN COMPLEJO DE GP120 COVALENTEMENTE UNIDO CON CD4 O A CONCANAVALINA DE SUCCINIL A. TAMBIEN SE HAN DESCUBIERTO PRUEBAS INMUNOLOGICAS QUE UTILIZAN EL COMPLEJO O LOS ANTICUERPOS PARA EL MISMO PARA LA DETECCION DE INFECCIONES POR HIV.
ES94917313T 1993-05-07 1994-05-06 Complejos inmunogenicos del hiv. Expired - Lifetime ES2166779T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6092693A 1993-05-07 1993-05-07

Publications (1)

Publication Number Publication Date
ES2166779T3 true ES2166779T3 (es) 2002-05-01

Family

ID=22032603

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94917313T Expired - Lifetime ES2166779T3 (es) 1993-05-07 1994-05-06 Complejos inmunogenicos del hiv.

Country Status (10)

Country Link
US (6) US5843454A (es)
EP (1) EP0699077B1 (es)
JP (1) JPH08510246A (es)
AT (1) ATE207760T1 (es)
AU (1) AU680916B2 (es)
DE (1) DE69428896T2 (es)
DK (1) DK0699077T3 (es)
ES (1) ES2166779T3 (es)
PT (1) PT699077E (es)
WO (1) WO1994026305A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165710A (en) * 1989-10-23 2000-12-26 Robinson; James E. Method for immobilizing viral glycoproteins for use in solid-phase immunoassays
US20040076636A1 (en) * 1993-05-07 2004-04-22 Ranajit Pal HIV immunogenic complexes
NZ332588A (en) * 1996-05-15 2000-11-24 Altarex Inc Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
WO1998000535A2 (en) * 1996-06-28 1998-01-08 Dana-Farber Cancer Institute Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
US7063850B1 (en) * 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
FR2789590B1 (fr) * 1999-02-15 2003-01-17 Inst Rech Developpement Ird Compositions immunogenes utilisables comme vaccins
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
ATE358726T1 (de) * 1999-10-08 2007-04-15 Univ Maryland Biotech Inst Virus hüllprotein-rezeptorchimäre und deren verwendungen
US7311920B1 (en) * 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US6908612B2 (en) * 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
FR2799974B1 (fr) * 1999-10-25 2001-11-30 Aventis Pasteur Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
US6503736B1 (en) * 1999-11-12 2003-01-07 BIOMéRIEUX, INC. Antibodies to crosslinkers and methods for using the same
KR20030036819A (ko) 2000-09-22 2003-05-09 듀크 유니버시티 면역원
US7033593B2 (en) * 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
CA2431212A1 (en) * 2000-12-27 2002-07-25 Richard T. Wyatt Immunogenic proteoliposomes, and uses thereof
GB2390811B (en) * 2001-03-21 2006-01-18 Altarex Inc Therapeutic compositions that alter the immune response
EP1450857B1 (en) * 2001-10-16 2010-09-15 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
AU2003223600A1 (en) * 2002-04-11 2003-10-27 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
CA2484930A1 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
EP1504034B1 (en) * 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CA2482744C (en) * 2002-05-07 2013-11-26 Chiron Corporation Hiv envelope-cd4 complexes and hybrids
AU2002368055B2 (en) 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
CN1620307A (zh) * 2002-06-28 2005-05-25 扶桑药品工业株式会社 抗hiv剂
US20060014148A1 (en) * 2002-07-23 2006-01-19 Barton Haynes Igg fc/hiv-gp120/c3d fusion protien
JP4038679B2 (ja) * 2003-05-13 2008-01-30 住友電気工業株式会社 半導体レーザーバーの固定用治具
US8637234B2 (en) * 2004-04-16 2014-01-28 Uab Research Foundation Molecular scaffolds for HIV-1 epitopes
US8206720B2 (en) * 2004-06-08 2012-06-26 Novartis Vaccines & Diagnostics, Inc Fusion proteins comprising CD4 minimal modules and invasin polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutraliziation epitopes
WO2006026097A2 (en) * 2004-08-25 2006-03-09 Vijay Ramakrishnan Pegylation of antibodies against hiv
WO2006044410A2 (en) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
WO2006050219A2 (en) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US8168194B2 (en) * 2005-02-03 2012-05-01 Novartis Vaccines & Diagnostics, Inc. Fusion proteins comprising CD4 minimal modules and human immunodeficiency virus (HIV) Tat scaffold polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutralization epitopes
WO2006091455A2 (en) * 2005-02-18 2006-08-31 Uab Research Foundation Molecular scaffolds for hiv-1 immunogens
EP1934605B1 (en) * 2005-09-22 2014-03-26 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US20100104580A1 (en) * 2008-09-03 2010-04-29 Philadelphia Health & Education Corporation D/B/A Altered Immunogenic Landscape in HIV-1 Envelope Proteins
US8340810B2 (en) * 2008-10-31 2012-12-25 Spectra Logic Corp. Robotic storage library with queued move instructions and method of queuing such instructions
US20110212119A1 (en) * 2008-10-31 2011-09-01 Proteonova, Inc. Methods for making hiv vaccines and related compositions
WO2011097511A1 (en) 2010-02-05 2011-08-11 The United States Of America, As Represented By The Secretary Department Of Health & Human Services REGULATORY B CELLS (tBREGS) AND THEIR USE
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
CA2836468C (en) 2011-05-17 2021-05-04 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US20150175678A1 (en) * 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
AU2014352638B2 (en) 2013-11-25 2018-08-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control HIV infection
WO2015120440A2 (en) * 2014-02-10 2015-08-13 Dana-Farber Cancer Institute, Inc. Cd4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies
US9975848B2 (en) 2014-08-13 2018-05-22 The Trustees Of The University Of Pennsylvania Inhibitors of HIV-1 entry and methods of use thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE108335T1 (de) * 1989-03-03 1994-07-15 Microgenesys Inc Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen.
EP0550516A1 (en) * 1990-09-28 1993-07-14 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus

Also Published As

Publication number Publication date
AU680916B2 (en) 1997-08-14
US5843454A (en) 1998-12-01
EP0699077B1 (en) 2001-10-31
PT699077E (pt) 2002-04-29
DK0699077T3 (da) 2002-01-21
AU6907394A (en) 1994-12-12
WO1994026305A1 (en) 1994-11-24
JPH08510246A (ja) 1996-10-29
DE69428896D1 (de) 2001-12-06
US20030039663A1 (en) 2003-02-27
US5518723A (en) 1996-05-21
US6465172B1 (en) 2002-10-15
ATE207760T1 (de) 2001-11-15
US6030772A (en) 2000-02-29
EP0699077A1 (en) 1996-03-06
US6328973B1 (en) 2001-12-11
DE69428896T2 (de) 2002-06-20

Similar Documents

Publication Publication Date Title
ES2166779T3 (es) Complejos inmunogenicos del hiv.
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
ES2104556T3 (es) Peptidos que tienen propiedades inmunologicas de hiv-2.
FI903292A0 (fi) T-cellepitop som baerarmolekyler foer konjugerade vacciner.
BG95337A (bg) Ваксиниране и методи срещу заболявания,резултат от патогенни отговори на т-клетъчно специфични популации
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
ES2032802T3 (es) Sucedaneo de la sangre, semisintetico, extrapuro.
ES2118109T3 (es) Antigenos polisacaridos de streptococcus pneumoniae.
ATE306938T1 (de) Verwendung von cpg als adjuvans für hivimpstoff
YU28392A (sh) Vakcina koja sadrži glikoprotein d i 3deacilovani monofosforil lipid a
ES2174837T3 (es) Conjugados de saponina-antigeno y su utilizacion.
HUP0204250A1 (hu) HIV-protein vagy- polinukleotid alkalmazása vakcina előállítására
CY1108299T1 (el) Πεπτιδια του ιου ανθρωπινης ανοσοανεπαρκειας (hiv), αντιγονα και συνθεσεις εμβολιου
AR114627A1 (es) Composición inmunogénica
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
EP2302059A8 (en) Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization
ES2074062T3 (es) Inmunoensayo para antigenos hiv-1 que utilizan fragmentos de f(ab')2 como sonda.
ES2062330T3 (es) Conjugados.
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
IL89012A (en) Peptides eliciting t-cell cytotoxicity against hiv, pharmaceutical compositions containing the same, and kits for detecting hiv infection containing the same
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
DE69029937D1 (de) FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER
DE58909850D1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
NO175846C (no) Fremgangsmåte for å oppnå et immunogen
ATE108335T1 (de) Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen.